Tilray stock tests $3.34 support amid net loss and cannabis revenue decline

Tilray stock tests $3.34 support amid net loss and cannabis revenue decline
Tilray drops 6.72% to $3.47 today

Tilray (TLRY) stock is trading at $3.47, reflecting a decline of 6.72% compared to the previous session. The price sits below its key moving averages, signaling broad short- and long-term weakness.

TLRY price prediction
24H 0.34%
$2.93
48H 0.34%
$2.93
7D 4.11%
$3.04
1M -32.19%
$1.98
3M -49.66%
$1.47
6M -68.15%
$0.93
12M -81.51%
$0.54
Current price: $2.92 0.1076 3.83%
Closed 11/06
Daily range 2.75 Arrow from to Icon 2.93
Weekly range 2.52 Arrow from to Icon 3.00
Loading...

Highlights

  • Tilray Brands Inc reported record revenue of $257.1 million for the first quarter of 2027, up 23% year over year.
  • Despite strong beverage segment growth of 82% to $101.5 million, Tilray posted a net loss of $40 million as cannabis revenue fell 13%.
  • Shares of Tilray fell 6.72% to $3.47, trading below key averages with high probability of a move to the $3.34 to $3.73 range.

Mixed operating results as cannabis revenue declines and beer surges

Tilray Brands Inc reported record revenue of $257.1 million for the first quarter of 2027, representing a 23% year-over-year increase that highlights ongoing expansion in both its core and newly acquired businesses. Despite a 35% rise in gross profit and significant growth in the beverage segment, which climbed 82% to $101.5 million following the BrewDog acquisition, the company posted a net loss of $40 million, or $0.32 per share. The decline in cannabis revenue by 13% to $56.1 million and continued operating losses weighed on quarterly results, while the firm maintained its full-year EBITDA guidance and improved its cash position and debt reduction, though price action has remained under broader selling pressure.

Tilray Brands Inc. asset chart
Tilray Brands Inc. price dynamics. Source: TradingView.

Sell signals persist as momentum remains neutral and oversold

On the technical front, TLRY/USD faces overhead resistance at the Ichimoku Kijun, which stands at $3.7. The stock is trading below the MA-20, MA-50, and well under the long-term MA-200 on the hourly chart, pointing to persistent weakness across all observed periods. Key support is found at $3.34, with immediate resistance at $3.7. Most momentum signals—including both MACD and ADX—are neutral, while RSI and CCI indicate ongoing sell pressure. Stochastic RSI now signals oversold territory, and Bull/Bear Power points to some buyer presence amid broader sell dominance. The Awesome Oscillator remains neutral and does not confirm a clear trend.

Consolidation outlook as volatility persists near support levels

In the near term, TLRY is likely to trade within the $3.34 to $3.73 band, reflecting typical volatility for the stock. The baseline scenario envisions a sideways consolidation, with a high likelihood of continued pressure or drift toward support levels. An upside scenario could briefly develop if the price breaks above $3.7, shifting focus to higher resistance levels. However, failure to hold the $3.34 support would expose TLRY to further losses.

Viktoras Karapetjanc, expert at Traders Union, sees Tilray’s ongoing revenue growth as a sign of successful diversification, particularly with the strong expansion in beverages. He believes improved margins and a stronger balance sheet signal resilience, even as the cannabis segment faces continued pressure. Technicals and sentiment remain weak, but positive fundamentals limit the downside risk in the near term. "If $3.34 support holds, I expect the stock to stabilize and potentially rebound on any shifts in sector sentiment or stronger execution."

Previously it was reported that short- and medium-term momentum in Tilray shares had improved ahead of earnings, suggesting a potential shift in trend. The latest results and ongoing technical weakness now signal increased downside risk, with $3.34 emerging as a critical support level for traders to monitor.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.